Lantheus (LNTH)
(Delayed Data from NSDQ)
$65.56 USD
+0.36 (0.55%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.57 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.56 USD
+0.36 (0.55%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.57 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Here's Why Lantheus Holdings (LNTH) Gained But Lagged the Market Today
by Zacks Equity Research
The latest trading day saw Lantheus Holdings (LNTH) settling at $65.56, representing a +0.55% change from its previous close.
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
by Zacks Equity Research
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lantheus Holdings (LNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) reachead $65.21 at the closing of the latest trading day, reflecting a +1.24% change compared to its last close.
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
by Zacks Equity Research
Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.
Why Lantheus Holdings (LNTH) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Lantheus (LNTH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should You Buy Encompass Health (EHC) Ahead of Q1 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q1 results are likely to benefit on the back of growing patient volumes and commendable expansion initiatives.
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Lantheus Holdings (LNTH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Elevance Health (ELV), CD&R to Unveil Primary Care Offering
by Zacks Equity Research
Elevance Health (ELV) forms an alliance with CD&R to enhance primary care delivery by making collective use of the partners' assets and subsequently, reduce overall costs of care.
Lantheus Holdings (LNTH) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) closed the most recent trading day at $60.25, moving -0.89% from the previous trading session.
Here's Why Lantheus Holdings (LNTH) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), ADMA Biologics (ADMA), Lantheus (LNTH) and Skyward (SKWD) are well-poised to gain.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Lantheus Holdings (LNTH) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Lantheus Holdings (LNTH) reachead $60.42 at the closing of the latest trading day, reflecting a +1.14% change compared to its last close.
Why HCA Healthcare (HCA) is a Smart Addition to Your Portfolio
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on growing patient volumes, buyouts, effective telehealth services and a notable financial stand.
Why You Should Add Ensign Group (ENSG) to Your Portfolio Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on sustained top-line growth, a growing healthcare portfolio and solid operating cash flows.
Is Trending Stock Lantheus Holdings, Inc. (LNTH) a Buy Now?
by Zacks Equity Research
Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Lantheus Holdings (LNTH) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the closing of the recent trading day, Lantheus Holdings (LNTH) stood at $59.19, denoting a +0.54% change from the preceding trading day.
5 Medical Product Stocks to Buy Amid Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.